by Backoffice | Nov 30, 2022 | Trial results
The Danish Medicines Agency has November 23rd, 2022, approved the un-blinded phase I dose-titrating clinical trial where children with autism and signs of leaky gut syndrome are treated with allogeneic adipose-derived mesenchymal stem cells (ASCs). The children will...
by Backoffice | Nov 4, 2022 | Studies and testing
The Danish National Center for Ethics has November 2nd, 2022, approved the un-blinded phase I clinical trial with dose-titrating of allogeneic adipose-derived mesenchymal stem cells (ASCs) for treatment of children with autism. The project is a collaboration between...
